Melanoma Journal Articles for April 2018
Clinical Cancer Research
The Need for Neddylation: A Key to Achieving NED in Uveal Melanoma
Jessica Yang, Omid Hamid and Richard D. Carvajal
DOI: 10.1158/1078-0432.CCR-18-0020
Journal of Translational Medicine
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
Michael F. Gowen†, Keith M. Giles†, Danny Simpson†, Jeremy Tchack, Hua Zhou, Una Moran, Zarmeena Dawood, Anna C. Pavlick, Shaohui Hu, Melissa A. Wilson, Hua Zhong, Michelle Krogsgaard, Tomas Kirchhoff and Iman Osman
Journal of Translational Medicine201816:82
https://doi.org/10.1186/s12967-018-1452-4
Received: 10 January 2018
Accepted: 15 March 2018
Published: 2 April 2018
Dove Press
miR-495 inhibits proliferation, migration, and invasion and induces apoptosis via inhibiting PBX3 in melanoma cells
Authors Chen G, Xie Y
Received 22 September 2017
Accepted for publication 31 December 2017
Published 5 April 2018 Volume 2018:11 Pages 1909—1920
DOI https://doi.org/10.2147/OTT.S152362
Management of Metastatic Melanoma in 2018
Howard L. Kaufman, MD1; Kim Margolin, MD2; Ryan Sullivan, MD3
JAMA Oncol. Published online April 5, 2018. doi:10.1001/jamaoncol.2018.0170
Cancer Discovery
Immune Checkpoint Blockade Is Active in Melanoma Brain Metastases
Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, et al.
DOI: 10.1158/2159-8290.CD-RW2018-058
Published OnlineFirst April 6, 2018
Annals of Surgical Oncology
Patterns of Treatment Failure in Patients with Sinonasal Mucosal Melanoma
Moran Amit, MD, PhD1 , Samantha Tam, MD1 , Ahmed S. Abdelmeguid, MD1 , Michael E. Kupferman, MD1 , Shirley Y. Su, MBBS1 , Shaan M. Raza, MD2 , Franco DeMonte, MD2 , and Ehab Y. Hanna, MD1,3
First Online: 06 April 2018
https://doi.org/10.1245/s10434-018-6465-y
Case Reports in Plastic Surgery and Hand Surgery
Development of a primary melanoma in situ within a full-thickness skin graft overlying a free muscle flap: a case report
Robert J. Dabek, Nemanja Baletic,Harrison McUmber,Brian Nahed,Alex Haynes,Kyle R. Eberlin & show all
Pages 23-26 | Received 22 Jan 2018, Accepted 10 Mar 2018, Published online: 06 Apr 2018
https://doi.org/10.1080/23320885.2018.1452615
Annals of Oncology
Surveillance imaging with FDG-PET/CT in the post-operative follow-up of stage 3 melanoma
J Lewin L Sayers D Kee I Walpole A Sanelli L te Marvelde A Herschtal J SpillaneD Gyorki D Speakman … Show more
Author Notes
Annals of Oncology, mdy124, https://doi.org/10.1093/annonc/mdy124
Published: 12 April 2018
Science – Translational medicine
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Natalie J. Neubert1,*, Martina Schmittnaegel2,*, Natacha Bordry1,*, Sina Nassiri2, Noémie Wald1, Christophe Martignier1, Laure Tillé1, Krisztian Homicsko1,2, William Damsky3, Hélène Maby-El Hajjami1, Irina Klaman4, Esther Danenberg5, Kalliopi Ioannidou1, Lana Kandalaft5, George Coukos1,5, Sabine Hoves4, Carola H. Ries4,
Silvia A. Fuertes Marraco1, Periklis G. Foukas5,†, Michele De Palma2,‡,§ and
Daniel E. Speiser1,‡,§
Science Translational Medicine 11 Apr 2018:
Vol. 10, Issue 436, eaan3311
DOI: 10.1126/scitranslmed.aan3311
Journal of the national cancer institute
A Nonsynonymous Variant in the GOLM1 Gene in Cutaneous Malignant Melanoma
Craig C Teerlink Chad Huff Jeff Stevens Yao Yu Sheri L Holmen Mark R SilvisKirby Trombetti Hua Zhao Douglas Grossman James M Farnham … Show more
Author Notes
JNCI: Journal of the National Cancer Institute, djy058,https://doi.org/10.1093/jnci/djy058
Published: 11 April 2018
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
The Lancet. Oncology, ISSN: 1474-5488
Publication Year: 2018
BMC Cancer
MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells
Yuxia Li, Jie Zhang, Yajing Liu, Bingyue Zhang, Fubo Zhong, Shubin Wang and Zhengyu Fang
BMC Cancer201818:404
https://doi.org/10.1186/s12885-018-4233-9
Received: 20 September 2017
Accepted: 15 March 2018
Published: 11 April 2018
Clinical Cancer Research
BRAF and MEK inhibitors increase PD1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD1 antibody
Martina Sanlorenzo, Igor Vujic, Arianna Floris, Mauro Novelli, Loretta Gammaitoni, Lidia Giraudo, Marco Macagno, Valeria Leuci, Ramona Rotolo, Chiara Donini, Marco Basiricò, Pietro Quaglino, Maria Teresa Fierro, Silvia Giordano, Maria Sibilia, Fabrizio Carnevale-Schianca, Massimo Aglietta and Dario Sangiolo
DOI: 10.1158/1078-0432.CCR-17-1914
Cancer Discovery
Adjuvant Therapy for Melanoma Prolongs RFS
DOI: 10.1158/2159-8290.CD-NB2018-047
Published OnlineFirst April 15, 2018
New England Journal of Medicine
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
Alexander M.M. Eggermont, M.D., Ph.D., Christian U. Blank, M.D., Ph.D., Mario Mandala, M.D., Georgina V. Long, M.D., P.D., Victoria Atkinson, M.D., Stéphane Dalle, M.D., Andrew Haydon, M.D., Mikhail Lichinitser, M.D., Adnan Khattak, M.D., Matteo S. Carlino, M.D., Ph.D., Shahneen Sandhu, M.D., James Larkin, M.D., et al.
April 15, 2018
DOI: 10.1056/NEJMoa1802357
The Great Debate at “Melanoma Bridge”, Napoli, December 2nd, 2017
Paolo A. Ascierto, Corrado Caracò, Jeffrey E. Gershenwald, Omid Hamid, Merrick Ross, Ryan J. Sullivan and Igor Puzanov
Journal of Translational Medicine201816:101
https://doi.org/10.1186/s12967-018-1477-8
Received: 20 March 2018
Accepted: 6 April 2018
Published: 17 April 2018
Journal of Surgical Oncology
Intralesional PV?10 for the treatment of in?transit melanoma metastases—Results of a prospective, non?randomized, single center study
Tavis A. Read BMedSc, MBBS, Aaron Smith BMedSc, MBBS, Janine Thomas BHSc, Michael David BSc Hons, MSc, PhD, Matthew Foote MBBS, FRANZCR, Michael Wagels BMedSc, MBBS, PhD, FRACS, Andrew Barbour MBBS, PhD, FRACS, B. Mark Smithers MBBS, FRACS, FRCS Eng
First published: 12 March 2018 https://doi.org/10.1002/jso.24921
JAMA Ophthalmology – Ophthalmic Images
March 8, 2018
Cutaneous Melanoma Metastatic to Anterior Lens Capsule
Samantha K. Paul, ScB1; Lin Chou, MD2; Carol L. Shields, MD3
JAMA Ophthalmol. 2018;136(3):e180095. doi:10.1001/jamaophthalmol.2018.0095
The Lancet
Novel gene variant for melanoma predisposition
Manjulika Das
Published: 19 April 2018
DOI: https://doi.org/10.1016/S1470-2045(18)30319-X
Clinical Cancer Research
Combined BRAF and HSP90 inhibition in patients with unresectable BRAF V600E mutant melanoma
Zeynep Eroglu, Yian Ann Chen, Geoffrey T Gibney, Jeffrey S. Weber, Ragini R. Kudchadkar, Nikhil I Khushalani, Joseph Markowitz, Andrew S Brohl, Leticia F. Tetteh, Howida Ramadan, Gina Arnone, Jiannong Li, Xiuhua Zhao, Ritin Sharma, Lancia N.F. Darville, Bin Fang, Inna Smalley, Jane L. Messina, John M. Koomen, Vernon K. Sondak and Keiran S.M. Smalley
DOI: 10.1158/1078-0432.CCR-18-0565
BioRix
The dynamics of ERK signaling in melanoma, and the response to BRAF or MEK inhibition, are cell cycle dependent.
View ORCID ProfileChloe May Simpson, Chris Bakal
doi: https://doi.org/10.1101/306571
Posted April 23, 2018.
Biomolecules 2018, 8(2), 21; https://doi.org/10.3390/biom8020021
Circulating MicroRNA Biomarkers in Melanoma: Tools and Challenges in Personalised Medicine
Sophie L. Mumford 1,Benjamin P. Towler 1,Amy L. Pashler 1,Onur Gilleard 2,Yella Martin 3 and Sarah F. Newbury 1,*
Received: 9 March 2018 / Revised: 20 April 2018 / Accepted: 23 April 2018 / Published: 26 April 2018
T cell mediated immunity after combination therapy with intralesional PV-10 and blockade of the PD-1/PD-L1 pathway in a murine melanoma model
Hao Liu , Amy Weber , Jennifer Morse, Krithika Kodumudi, Ellen Scott, John Mullinax, Amod A. Sarnaik , Shari Pilon-Thomas
- Published: April 25, 2018
- https://doi.org/10.1371/journal.pone.0196033